TY - JOUR
T1 - Correlation of p53, MDM2 and p14ARF protein expression in human esophageal squamous cell carcinoma
AU - Cheng, Tzu Hao
AU - Hsu, Po Kuei
AU - Li, Anna Fen Yau
AU - Hung, I. Chun
AU - Huang, Min Hsiung
AU - Hsu, Han Shui
N1 - Funding Information:
Acknowledgments The study was supported by grants from the National Science Council of Taiwan to HS Hsu (NSC-96-2314-B-075-027) and TH Cheng (NSC-93-2320-B-010-063).
PY - 2009
Y1 - 2009
N2 - Purpose: To determine the interrelationships of p53, MDM2, and p14 ARF protein expression in primary esophageal squamous cell carcinoma (ESCC) and their prognostic value in ESCC. Methods: In total, 119 patients treated for ESCC with esophagectomy were enrolled in this study. Demographic and clinical data including gender, age, depth of tumor invasion, lymph node involvement, and 5-year survival rate were collected by chart review. p53, MDM2, and p14ARF were detected immunohistochemically in the resected tumors to evaluate their usefulness as biomarkers of clinical outcome. Results: p53, MDM2, and p14ARF were expressed in 61 (51.3%), 34 (28.6%), and 22 (18.5%) of 119 tumor specimens, respectively. Overall, p53 protein expression was positively correlated with MDM2 (P = 0.024) and p14ARF expression (P = 0.026). In addition, p14ARF expression was most often found in specimens that were positive for both p53 and MDM2. Changes in the p53, MDM2, and p14ARF protein levels were not correlated with 5-year survival rate. Conclusions: Expression of p53 protein correlates with increased MDM2 and p14ARF protein levels in ESCC. In addition, status of p53 (wild-type versus mutant) rather than expression level of p53, MDM2, or p14 ARF is likely to be the more critical determinant of clinical outcome.
AB - Purpose: To determine the interrelationships of p53, MDM2, and p14 ARF protein expression in primary esophageal squamous cell carcinoma (ESCC) and their prognostic value in ESCC. Methods: In total, 119 patients treated for ESCC with esophagectomy were enrolled in this study. Demographic and clinical data including gender, age, depth of tumor invasion, lymph node involvement, and 5-year survival rate were collected by chart review. p53, MDM2, and p14ARF were detected immunohistochemically in the resected tumors to evaluate their usefulness as biomarkers of clinical outcome. Results: p53, MDM2, and p14ARF were expressed in 61 (51.3%), 34 (28.6%), and 22 (18.5%) of 119 tumor specimens, respectively. Overall, p53 protein expression was positively correlated with MDM2 (P = 0.024) and p14ARF expression (P = 0.026). In addition, p14ARF expression was most often found in specimens that were positive for both p53 and MDM2. Changes in the p53, MDM2, and p14ARF protein levels were not correlated with 5-year survival rate. Conclusions: Expression of p53 protein correlates with increased MDM2 and p14ARF protein levels in ESCC. In addition, status of p53 (wild-type versus mutant) rather than expression level of p53, MDM2, or p14 ARF is likely to be the more critical determinant of clinical outcome.
KW - Esophageal cancer
KW - Immunohistochemistry
KW - MDM2
KW - P14
KW - P53
UR - http://www.scopus.com/inward/record.url?scp=70349569040&partnerID=8YFLogxK
U2 - 10.1007/s00432-009-0605-5
DO - 10.1007/s00432-009-0605-5
M3 - Article
C2 - 19488782
AN - SCOPUS:70349569040
SN - 0171-5216
VL - 135
SP - 1577
EP - 1582
JO - Journal of Cancer Research and Clinical Oncology
JF - Journal of Cancer Research and Clinical Oncology
IS - 11
ER -